Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines

Oncology Letters

Volumn 9, Issue 4, 2015, Pages 1861-1868

  Yuan, Tein Ming ^a,b   Liang, Ruei Yue ^a   Chueh, Pin Ju ^a   Chuang, Show Mei ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b FENG YUAN HOSPITAL   (Taiwan)

Author keywords

Cytotoxicity; Drug resistance; P glycoprotein; Ribophorin II

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PROTEIN P21; PROTEIN P53; RIBOPHORIN II; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC50; MTS ASSAY; PREDICTIVE VALUE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; SURVIVAL RATE; WESTERN BLOTTING;

EID: 84923196364     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.2900     Document Type: Article

References (18)

1. Davis MP, Dewald GW, Pierre RV and Hoagland HC: Hematologic manifestations associated with deletions of the long arm of chromosome 20. Cancer Genet Cytogenet 12: 63-71, 1984.
2. Löffler C, Rao VV and Hansmann I: Mapping of the ribophorin II (RPN II) gene to human chromosome 20q12-q13.1 by in-situ hybridization. Hum Genet 87: 221-222, 1991.
3. Roulston D, Espinosa R III, Stoffel M, Bell GI and Le Beau MM: Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood 82: 3424-3429, 1993.
4. Testa JR, Kinnealey A, Rowley JD, Golde DW and Potter D: Deletion of the long arm of chromosome 20 [del(20)(q11)] in myeloid disorders. Blood 52: 868-877, 1978.
5. Crimaudo C, Hortsch M, Gausepohl H and Meyer DI: Human ribophorins I and II: the primary structure and membrane topology of two highly conserved rough endoplasmic reticulum-specific glycoproteins. EMBO J 6: 75-82, 1987.
6. Hortsch M, Avossa D and Meyer DI: Characterization of secretory protein translocation: ribosome-membrane interaction in endoplasmic reticulum. J Cell Biol 103: 241-253, 1986.
7. Kelleher DJ, Kreibich G and Gilmore R: Oligosaccharyltransferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kd protein. Cell 69: 55-65, 1992.
8. Kelleher DJ and Gilmore R: An evolving view of the eukaryotic oligosaccharyltransferase. Glycobiology 16: 47R-62R, 2006.
9. Kaushal M, Mishra AK, Sharma J, Zomawia E, Kataki A, Kapur S and Saxena S: Genomic alterations in breast cancer patients in betel quid and non betel quid chewers. PLoS One 7: e43789, 2012.
10. Zhu J, He J, Liu Y, Simeone DM and Lubman DM: Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray. J Proteome Res 11: 2272-2281, 2012.
11. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K and Ochiya T: RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 14: 939-948, 2008.
12. De Souza R, Zahedi P, Badame RM, Allen C and Piquette-Miller M: Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Mol Cancer Ther 10: 1289-1299, 2011.
13. Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Nagai Y, Ishimoto T, Baba Y, Mimori K and Baba H: RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer 107: 1233-1238, 2012.
14. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63: 12-31, 2007.
15. Stanley LA, Horsburgh BC, Ross J, Scheer N and Wolf CR: Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior. Drug Metab Rev 41: 27-65, 2009.
16. Gottesman MM and Ling V: The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580: 998-1009, 2006.
17. Chen KG and Sikic BI: Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 18: 1863-1869, 2012.
18. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE and Gottesman MM: Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat 15: 62-69, 2012.